Article (Scientific journals)
Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.
de Vries, Tim A C; Hemels, Martin E W; Cools, Frank et al.
2021In Acta Cardiologica, 76 (4), p. 431-439
Peer Reviewed verified by ORBi
 

Files


Full Text
00015385.2020.pdf
Author postprint (3.02 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anticoagulants; Factor Xa Inhibitors; Pyridines; Thiazoles; NDU3J18APO (edoxaban); Aged; Atrial Fibrillation/complications/drug therapy/epidemiology; Belgium/epidemiology; Europe/epidemiology; Factor Xa Inhibitors/therapeutic use; Humans; Netherlands/epidemiology; Prospective Studies; Pyridines/therapeutic use; Thiazoles/therapeutic use; Treatment Outcome; clinical trial, phase IV; anticoagulants; haemorrhage; off-label use; stroke; thromboembolism
Abstract :
[en] BACKGROUND: Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban. METHODS: With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 mL/min, weight ≤60 kg, and/or use of strong p-glycoprotein inhibitors) of patients from Belgium and the Netherlands (BeNe) with those from other European countries (OEC). RESULTS: Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA(2)DS(2)-VASc (mean: 2.8 vs 3.2) and HAS-BLED scores (mean: 2.4 vs 2.6). Patients from BeNe less often had hypertension (61.6% vs 80.4%), and/or diabetes mellitus (17.3% vs 23.1%) than patients from OEC. Moreover, relatively fewer patients in BeNe were prescribed the reduced dose of 30 mg edoxaban (14.8%) than in OEC (25.4%). Overall, edoxaban was dosed according to label in 83.1% of patients. Yet, 30 mg edoxaban was prescribed in the absence of any dose reduction criteria in 36.9% of 30 mg users (5.5% of all patients) in BeNe compared with 35.5% (9.0% of all patients) in OEC. CONCLUSION: There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation. TRIAL REGISTRATION: NCT02944019; Date of registration: October 24, 2016.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
de Vries, Tim A C ;  Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands. ; Department of Cardiology, Amsterdam Medical Centres/University of Amsterdam
Hemels, Martin E W ;  Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands. ; Department of Cardiology, Radboud University Medical Centre, Nijmegen, The
Cools, Frank ;  Department of Cardiology, General Hospital Klinieken Noord-Antwerpen, Brasschaat
Crijns, Harry J G M ;  Department of Cardiology, Maastricht University Medical Centre, Maastricht, The
Yperzeele, Laetitia ;  Department of Neurosurgery, University Hospital Antwerp, Antwerp, Belgium.
Vanacker, Peter;  Department of Neurosurgery, University Hospital Antwerp, Antwerp, Belgium. ; Department of Neurology, General Hospital Groeninge, Kortrijk, Belgium.
Blankoff, Ivan;  Department of Cardiology, Civil Hospital Marie Curie, Charleroi, Belgium.
LANCELLOTTI, Patrizio  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Mairesse, Georges H ;  Department of Cardiology, Cliniques du Sud-Luxembourg, Arlon, Belgium.
de Veer, Anne ;  Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Casado Arroyo, Ruben;  Department of Cardiology, Hospital Erasme, Anderlecht, Belgium.
Catez, Emmanuel ;  Department of Cardiology, Brugmann University Hospital, Brussels, Belgium.
de Pauw, Michel ;  Department of Cardiology, Ghent University Hospital, Ghent, Belgium.
Vanassche, Thomas ;  Department of Cardiology, Leuven University Hospital, Leuven, Belgium.
de Asmundis, Carlo ;  Department of Cardiology, University Hospital Brussels, Brussels, Belgium.
Kirchhof, Paulus ;  Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. ; The Atrial Fibrillation NETwork (AFNET), Münster, Germany.
De Caterina, Raffaele ;  Department of Cardiology, University of Pisa, Pisa, Italy.
de Groot, Joris R ;  Department of Cardiology, Amsterdam Medical Centres/University of Amsterdam
ETNA-AF-Europe principal investigators from Belgium and the, Netherlands
More authors (9 more) Less
Language :
English
Title :
Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.
Publication date :
June 2021
Journal title :
Acta Cardiologica
ISSN :
0001-5385
eISSN :
1784-973X
Volume :
76
Issue :
4
Pages :
431-439
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 18 May 2022

Statistics


Number of views
155 (0 by ULiège)
Number of downloads
115 (0 by ULiège)

Scopus citations®
 
2
Scopus citations®
without self-citations
1
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi